{"protocolSection": {"identificationModule": {"nctId": "NCT02322788", "orgStudyIdInfo": {"id": "D4711C00001"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3", "officialTitle": "A Randomised, Double-blind, Double-dummy, Multi-site, Phase III, Single Dose, 4-way Cross-over Pharmacodynamic Study Evaluating the Efficacy of Bricanyl Turbuhaler M3 Compared to Bricanyl Turbuhaler M2 by Studying the Protective Effect on Methacholine Induced Bronchoconstriction in Patients With Stable, Mild to Moderate Asthma"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-03"}, "primaryCompletionDateStruct": {"date": "2015-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-11-26", "studyFirstSubmitQcDate": "2014-12-19", "studyFirstPostDateStruct": {"date": "2014-12-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-09-16", "resultsFirstSubmitQcDate": "2016-09-16", "resultsFirstPostDateStruct": {"date": "2016-11-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-23", "lastUpdatePostDateStruct": {"date": "2017-01-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M2 by studying the protective effect on methacholine induced bronchoconstriction in patients with stable, mild to moderate asthma", "detailedDescription": "The study will include female and male patients, between 18 and 65 years old, with stable, mild to moderate asthma who are on short acting \u03b22-agonist (SABA) alone, on low dose inhaled corticosteroid (ICS) (200-400 \u00b5g budesonide or corresponding) or on a combination of low dose ICS and long acting \u03b22-agonists (LABA). Approximately 60 patients will be randomised in order to have 49 completed.\n\nThe primary objective is to demonstrate therapeutic equivalence between Bricanyl Turbuhaler M3 and Bricanyl Turbuhaler M2 using bronchoprotective effect. Outcome measure: PC20 (Methacholine provocative concentration causing a 20% drop in FEV1). The safety objective is to compare safety of Bricanyl Turbuhaler M2 and Bricanyl Turbuhaler M3. Outcome measure Adverse Events/Serious.\n\nStudy period Q1 2015 - Q1 2016."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Inhalation, Pharmacodynamic, Patients,"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 95, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Bricanyl Turbuhaler M2, Active", "type": "ACTIVE_COMPARATOR", "description": "Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation", "interventionNames": ["Drug: Terbutaline sulphate"]}, {"label": "Bricanyl Turbuhaler M3, Active", "type": "ACTIVE_COMPARATOR", "description": "Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation", "interventionNames": ["Drug: Terbutaline sulphate"]}, {"label": "Turbuhaler M2, Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo powder for inhalation", "interventionNames": ["Drug: Placebo for terbutaline sulphate"]}, {"label": "Turbuhaler M3, Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo powder for inhalation", "interventionNames": ["Drug: Placebo for terbutaline sulphate"]}], "interventions": [{"type": "DRUG", "name": "Terbutaline sulphate", "description": "Bricanyl Turbuhaler M2", "armGroupLabels": ["Bricanyl Turbuhaler M2, Active"], "otherNames": ["Terbutaline sulphate powder for inhalation, 0.5 mg (metered dose) terbutaline per inhalation"]}, {"type": "DRUG", "name": "Terbutaline sulphate", "description": "Bricanyl Turbuhaler M3", "armGroupLabels": ["Bricanyl Turbuhaler M3, Active"], "otherNames": ["Terbutaline sulphate powder for inhalation, 0.4 mg (delivered dose) terbutaline per inhalation"]}, {"type": "DRUG", "name": "Placebo for terbutaline sulphate", "description": "Placebo Turbuhaler M2", "armGroupLabels": ["Turbuhaler M2, Placebo"], "otherNames": ["Placebo powder for inhalation"]}, {"type": "DRUG", "name": "Placebo for terbutaline sulphate", "description": "Placebo Turbuhaler M3", "armGroupLabels": ["Turbuhaler M3, Placebo"], "otherNames": ["Placebo powder for inhalation"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20)", "timeFrame": "4 cross-over treatments (<1 day each) with 2-10 days between treatment washout periods"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria: - Female and male aged 18 and 65 years.\n\n* At least 6 months of documented clinical diagnosis of asthma as defined by GINA 2012 or American Thoracic Society (Expert Panel Report 3 2007) prior to visit 1\n* Stable asthmatics on SABA alone, on low dose ICS (200-400 \u00b5g budesonide corresponding) or on fixed combination of low ICS/LABA\n* At the enrolment visit 1a, the visit baseline FEV1 must be \u226580 % of that predicted normal (NHANES III). For LABA patients the visit baseline FEV1 must be \u226580 % of that predicted normal (NHANES III) at both visit 1a and visit 1b. If not, the patient will be withdrawn from the study\n* At the enrolment visits 1a or 1b (LABA patients only) and at the end of run-in period, visit 2, eligible patients should demonstrate an airway responsiveness to methacholine PC20 \\<8 mg/mL. If not, the patient will be withdrawn from the study\n* Capable of using Turbuhaler inhalation device as judged by investigator. Exclusion Criteria: Diagnosed with COPD or history of cystic fibrosis, bronchiectasis or other respiratory diseases\n* Pregnancy, breast-feeding, lactation, or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures\n* Conditions which could alter airway reactivity to methacholine (e.g. pneumonia, upper respiratory tract infection, viral bronchitis and/or sinobronchitis) within past six weeks\n* Exacerbation due to asthma or change in asthma medication during the last 3 months prior to enrolment\n* Night time awakenings due to asthma symptoms on 2 consecutive nights during the last 4 weeks prior to enrolment\n* Smokers 6 months prior to the study start or with a history of smoking of more than 10 pack years (e.g. 20 cigarettes/day for at least 10 years, or 10 cigarettes/day for at least 20 years, or equal).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "G\u00f6ran Eckerwall, MD", "affiliation": "AstraZeneca M\u00f6lndal, Sweden", "role": "STUDY_DIRECTOR"}, {"name": "Leif Bjermer, MD, Professor", "affiliation": "Sk\u00e5nes University hospital, Lund", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Groningen", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Research Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}]}, "referencesModule": {"references": [{"pmid": "28232118", "type": "DERIVED", "citation": "Bjermer L, Gauvreau GM, Postma DS, O'Byrne PM, van den Berge M, Boulet LP, Beckman O, Persson T, Roman J, Carlholm M, Schutzer KM, Eckerwall G. Methacholine challenge tests to demonstrate therapeutic equivalence of terbutaline sulfate via different Turbuhaler(R) devices in patients with mild to moderate asthma: Appraisal of a four-way crossover design. Pulm Pharmacol Ther. 2017 Jun;44:1-6. doi: 10.1016/j.pupt.2017.02.004. Epub 2017 Feb 20."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 95 patients enrolled 34 were screen failures mainly due to not fulfilling specific randomization criteria on stability in asthma or sensitivity to methacholine challenge; 1 was withdrawal by subject; 72 entered run in period. A total of 60 patients were randomized to the 4 single-dose treatments with terbutaline in a crossover design.", "recruitmentDetails": "Patients with stable, mild to moderate asthma were enrolled. The first subject entered study on March 10, 2015 and the last subject completed study on November 5, 2015. Subjects were recuited from Site 1001 and 1002 in Canada, Site 7201 in Sweden, and Site 5001 in Netherlands.", "groups": [{"id": "FG000", "title": "M2 0.5 mg", "description": "0.5 mg terbutaline sulphate administered via Turbuhaler M2"}, {"id": "FG001", "title": "M2 1.5 mg", "description": "1.5 mg terbutaline sulphate administered via Turbuhaler M2"}, {"id": "FG002", "title": "M3 0.5 mg", "description": "0.5 mg terbutaline sulphate administered via Turbuhaler M3"}, {"id": "FG003", "title": "M3 1.5 mg", "description": "1.5 mg terbutaline sulphate administered via Turbuhaler M3"}], "periods": [{"title": "Visit 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "16"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "16"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Visit 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "15"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Visit 5", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Visit 6", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "15"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full analysis set", "groups": [{"id": "BG000", "title": "Overall", "description": "Total number of participants in the Full analysis set"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "60"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.1", "spread": "12.19"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "40"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "57"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20)", "populationDescription": "Efficacy analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/mL", "timeFrame": "4 cross-over treatments (<1 day each) with 2-10 days between treatment washout periods", "groups": [{"id": "OG000", "title": "M3 1.5 mg", "description": "1.5 mg terbutaline sulphate administered via Turbuhaler M3"}, {"id": "OG001", "title": "M3 0.5 mg", "description": "0.5 mg terbutaline sulphate administered via Turbuhaler M3"}, {"id": "OG002", "title": "M2 1.5 mg", "description": "1.5 mg terbutaline sulphate administered via Turbuhaler M2"}, {"id": "OG003", "title": "M2 0.5 mg", "description": "0.5 mg terbutaline sulphate administered via Turbuhaler M2"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17.70", "lowerLimit": "12.51", "upperLimit": "25.05"}, {"groupId": "OG001", "value": "9.88", "lowerLimit": "6.98", "upperLimit": "13.99"}, {"groupId": "OG002", "value": "20.10", "lowerLimit": "14.20", "upperLimit": "28.45"}, {"groupId": "OG003", "value": "10.78", "lowerLimit": "7.61", "upperLimit": "15.25"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "A linear mixed effect model based on restricted maximum likelihood analysis is used to estimate the treatment effect. PC20 in natural log scale is the response variable, treatment and period are the fixed effects, and patient within sequence is a random effect.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Estimated mean ratio", "paramValue": "1.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.52", "ciUpperLimit": "2.29"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "A linear mixed effect model based on restricted maximum likelihood analysis is used to estimate the treatment effect. PC20 in natural log scale is the response variable, treatment and period are the fixed effects, and patient within sequence is a random effect.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Estimated mean ratio", "paramValue": "1.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.46", "ciUpperLimit": "2.20"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "A linear mixed effect model based on restricted maximum likelihood analysis is used to estimate the treatment effect. PC20 in natural log scale is the response variable, treatment and period are the fixed effects, and patient within sequence is a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The details of the sample size calculation is document at Section 8.2 the study protocol.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Estimated mean ratio", "paramValue": "0.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.75", "ciUpperLimit": "1.13"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "A linear mixed effect model based on restricted maximum likelihood analysis is used to estimate the treatment effect. PC20 in natural log scale is the response variable, treatment and period are the fixed effects, and patient within sequence is a random effect.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The details of the sample size calculation is document at Section 8.2 the study protocol.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Estimated mean ratio", "paramValue": "0.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.72", "ciUpperLimit": "1.08"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "During randomized treatment period from Visit 3 to Visit 6", "eventGroups": [{"id": "EG000", "title": "M2 0.5 mg", "description": "0.5 mg terbutaline sulphate administered via Turbuhaler M2", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 12, "otherNumAtRisk": 60}, {"id": "EG001", "title": "M2 1.5 mg", "description": "1.5 mg terbutaline sulphate administered via Turbuhaler M2", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 10, "otherNumAtRisk": 60}, {"id": "EG002", "title": "M3 0.5 mg", "description": "0.5 mg terbutaline sulphate administered via Turbuhaler M3", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 7, "otherNumAtRisk": 60}, {"id": "EG003", "title": "M3 1.5 mg", "description": "1.5 mg terbutaline sulphate administered via Turbuhaler M3", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 13, "otherNumAtRisk": 60}], "otherEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 60}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Arthropod sting", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 60}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 60}]}, {"term": "Restlessness", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "G\u00f6ran Eckerwall, MD, PhD", "organization": "AstraZeneca R&D Gothenburg, SE-431 83 M\u00f6lndal, Sweden", "email": "goran.eckerwall@astrazeneca.com", "phone": "+46 708467664"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000013726", "term": "Terbutaline"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000013566", "term": "Sympathomimetics"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M13031", "name": "Oxymetazoline", "relevance": "LOW"}, {"id": "M13561", "name": "Phenylephrine", "relevance": "LOW"}, {"id": "M18666", "name": "Methacholine Chloride", "relevance": "LOW"}, {"id": "M16496", "name": "Terbutaline", "asFound": "Temodar", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "Repr", "name": "Reproductive Control Agents"}]}}, "hasResults": true}